...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Trial
Reply New Message
Back To Forum List View
Key Players
5
KayakerBC
Aug 31, 2016 10:08PM
Icon president Re: Key Players
3
SanFrancisco99
Sep 01, 2016 12:45AM
Trial
1
Hartland
Sep 07, 2016 08:16AM
Icon president Re: Trial
5
BearDownAZ
Sep 07, 2016 09:34AM
Re: Trial

Hartland
Sep 07, 2016 11:18AM
Icon president Re: Trial
3
BearDownAZ
Sep 07, 2016 11:48AM
Re: Trial

Hartland
Sep 07, 2016 07:29PM
Icon president Re: Trial
4
BearDownAZ
Sep 08, 2016 09:48AM
Re: Trial
3
Nextblockbuster
Sep 08, 2016 10:37AM

I'm not sure if there was a question there. But I do agree that since we are near cycle 4, based upon being 12 weeks from date of first dosing, this likely indicates that DLTs were not encountered in the beginning phases/cycle. A Zenith quarterly update or AGM would clear this up quick. In the meantime.........

4 Recommendations
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply